A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia

Trial Profile

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 May 2018

At a glance

  • Drugs Cytarabine (Primary) ; Decitabine (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Gemtuzumab ozogamicin (Primary) ; Idarubicin (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Mar 2018 Planned number of patients changed from 180 to 200.
    • 22 Mar 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2021.
    • 22 Mar 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top